MEDINET focuses on its clinical development which is designed to accumulate clinical evidence and experience on immuno-cell therapy in order to clarify therapeutic value of the therapy in cancer treatment, and believes that its clinical development will lead immuno-cell therapy to become widely used therapy in the public.

At present, MEDINET performs multiple clinical studies with leading medical institutions in regional communities, particularly university hospitals, as MEDINET intends to ensure further evaluation and validation of efficacy and safety in various types of immuno-cell therapy. MEDINET has obtained data of its existing technologies as well as newly developed technologies through those clinical studies, and will accelerate further clinical development along its R&D activities.

As another activity of the clinical development, MEDINET provides the Immuno-Cell Therapy Total Support Service specifically to the Department of Immunotherapeutics at the 22nd Century Medical and Research Center, the University of Tokyo Hospital. The University of Tokyo Hospital performs fundamental research for leading-edge therapeutics technology as well as clinical studies for immuno-cell therapy in various types of cancer by efficient use of interdepartmental cooperation within the Tokyo University Hospital. These clinical development activities will lead the therapy to become widely-used therapy in cancer treatment.

<Preventive Effect on Cancer Recurrence>
Immuno-cell therapy is a systemic therapy which can remove invisible cancer cells without serious ADRs (Adverse Drug Reactions,) even though cancer cells are discernible in diagnostic imaging. It is presumed that the therapy is used as a combination therapy with a standard therapy for preventive effect. As an example of such preventive effect, large-scale randomized comparative studies for preventive effect of immuno-cell therapy in cancer recurrence have been performed by National Cancer Center and Chiba Cancer Center. These studies demonstrated that groups, which are conducted immuno-cell therapy after surgery, had a lower rate of cancer recurrence and significantly showed higher survival rate than control groups. Please see further detailed information of those clinical studies in the following academic papers;-

■	Takayama T, et al, Lancet., 356(9232):802-7., Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. (2000)
■	Kimura H, et al, Cancer., 80(1):42-9., A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.(1997)

<Effect of Combination Therapy in Cancer Treatment>
Since cancer is a disease which is difficult to be cured by sole treatment, importance of multidisciplinary treatment against refractory cancer becomes widely concerned issue at a cancer board of medical institutions, which is comprised of specialists from various fields of cancer treatments. Therefore, it is expected to find an optimal multidisciplinary treatment among the standard therapies, such as surgery, radiotherapy, and chemotherapy, or advanced treatments, including immuno-cell therapy. For example, a combination therapy with lower dosage of anti-cancer drug and immuno-cell therapy after surgical resection or irradiation brings a certain therapeutic benefit with suppressed adverse effects. By such combination therapy, it has possibility for patient to maintain a higher QOL (quality of life,) compared with sole treatment of a standard therapy.

<Expansion of Indications>
Since immune cells have a similar mechanism to eliminate cancer cells and to remove virus-infected cells from human body, it is considered that immuno-cell therapy can be potentially applicable to viral infections. At present, there are some existing therapies for retractable viral diseases, such as Hepatitis C, whereas these therapies may be ineffective or may have adverse reactions to human body. In order to create a new treatment option, various clinical researches with immuno-cell therapy have already been performed in the field of viral infections. MEDINET also considers expanding its platform technology of immuno-cell therapy to various infectious diseases by taking advantage of accumulated experience in cancer immuno-cell therapy, and aims for establishing alternative choice for patients with lower adverse effects or higher therapeutic effect on retractable viral diseases.

MEDINET continues to establish infrastructure of clinical network with university hospitals and other leading medical institutions in regional communities in order to build clinical evidence of immuno-cell therapy. This activity will be also connected to build foundation of nationwide medical network for cancer patients to receive immuno-cell therapy.